{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:15:13Z","timestamp":1778840113242,"version":"3.51.4"},"reference-count":199,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.cld.2007.11.013","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T13:46:43Z","timestamp":1201873603000},"page":"53-80","source":"Crossref","is-referenced-by-count":33,"title":["Medical Treatment of Cholestatic Liver Disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Gustav","family":"Paumgartner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pusl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.cld.2007.11.013_bib1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"339","author":"Trauner","year":"1998","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.cld.2007.11.013_bib2","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.3748\/wjg.v12.i28.4445","article-title":"Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets","volume":"12","author":"Paumgartner","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib3","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/gast.2002.35948","article-title":"Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles","volume":"123","author":"Fickert","year":"2002","journal-title":"Gastroenterology"},{"issue":"30","key":"10.1016\/j.cld.2007.11.013_bib4","doi-asserted-by":"crossref","first-page":"11323","DOI":"10.1073\/pnas.0604772103","article-title":"Benefit of farnesoid X receptor inhibition in obstructive cholestasis","volume":"103","author":"Stedman","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1089-3261(05)70114-8","article-title":"Mechanisms of cholestasis","volume":"4","author":"Kullak-Ublick","year":"2000","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.gastro.2003.06.005","article-title":"Enterohepatic bile salt transporters in normal physiology and liver disease","volume":"126","author":"Kullak-Ublick","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/hep.1840140324","article-title":"Mechanisms and regulation of bile secretion","volume":"14","author":"Nathanson","year":"1991","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(02)00633-8","article-title":"The superfamily of organic anion transporting polypeptides","volume":"1609","author":"Hagenbuch","year":"2003","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00424-003-1130-z","article-title":"The sodium bile salt cotransport family SLC10","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pflugers Arch"},{"issue":"13","key":"10.1016\/j.cld.2007.11.013_bib11","doi-asserted-by":"crossref","first-page":"9626","DOI":"10.1074\/jbc.M004968200","article-title":"Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6","volume":"276","author":"Cui","year":"2001","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00424-006-0152-8","article-title":"The bile salt export pump","volume":"453","author":"Stieger","year":"2007","journal-title":"Pflugers Arch"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","article-title":"The apical conjugate efflux pump ABCC2 (MRP2)","volume":"453","author":"Nies","year":"2007","journal-title":"Pflugers Arch"},{"issue":"1 Suppl","key":"10.1016\/j.cld.2007.11.013_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(00)80411-0","article-title":"Hepatobiliary transport","volume":"32","author":"Kullak-Ublick","year":"2000","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2003.50331","article-title":"Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane","volume":"38","author":"Rius","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00008571-200404000-00001","article-title":"Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3\/ABCC3)","volume":"14","author":"Lee","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"38","key":"10.1016\/j.cld.2007.11.013_bib17","doi-asserted-by":"crossref","first-page":"36688","DOI":"10.1074\/jbc.M304011200","article-title":"Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis","volume":"278","author":"Bohan","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib18","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.20961","article-title":"OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia","volume":"42","author":"Ballatori","year":"2005","journal-title":"Hepatology"},{"issue":"1\u20133","key":"10.1016\/j.cld.2007.11.013_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbalip.2004.11.003","article-title":"Novel pathways of bile acid metabolism involving CYP3A4","volume":"1687","author":"Bodin","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1096\/fasebj.11.1.9034160","article-title":"Sulfation and sulfotransferases 1: sulfotransferase molecular biology: cDNAs and genes","volume":"11","author":"Weinshilboum","year":"1997","journal-title":"FASEB J"},{"issue":"21","key":"10.1016\/j.cld.2007.11.013_bib21","doi-asserted-by":"crossref","first-page":"22250","DOI":"10.1074\/jbc.M314111200","article-title":"Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice","volume":"279","author":"Assem","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1389200003339171","article-title":"UDP-glucuronosyltransferases","volume":"1","author":"King","year":"2000","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1021\/mp060010s","article-title":"Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations","volume":"3","author":"Zollner","year":"2006","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/jhep.2001.22646","article-title":"Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases","volume":"33","author":"Zollner","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","article-title":"Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis","volume":"38","author":"Zollner","year":"2003","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib26","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/hep.20682","article-title":"Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis","volume":"41","author":"Keitel","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib27","doi-asserted-by":"crossref","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/jhep.2001.26213","article-title":"Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver","volume":"34","author":"Donner","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jhep.2003.12.001","article-title":"Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat","volume":"40","author":"Denk","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib30","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1681\/ASN.V1061159","article-title":"Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma","volume":"10","author":"Schaub","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.V133595","article-title":"The MRP4\/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP","volume":"13","author":"van Aubel","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"4 Suppl 2","key":"10.1016\/j.cld.2007.11.013_bib32","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1097\/01.mcg.0000155551.37266.26","article-title":"Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis","volume":"39","author":"Trauner","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1089-3261(03)00135-1","article-title":"Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease","volume":"8","author":"Paumgartner","year":"2004","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","article-title":"Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"127","author":"Fickert","year":"2004","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.01.007","article-title":"Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor","volume":"128","author":"Svegliati-Baroni","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI200418385","article-title":"A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR","volume":"113","author":"Huang","year":"2004","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.cld.2007.11.013_bib37","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.cld.2007.11.013_bib38","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J\u00a0Med Chem"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","article-title":"Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans","volume":"129","author":"Marschall","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0016-5085(03)01068-0","article-title":"Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice","volume":"125","author":"Wagner","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.20568","article-title":"No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis","volume":"41","author":"Dilger","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0016-5085(94)94899-2","article-title":"Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid","volume":"106","author":"Jazrawi","year":"1994","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.cld.2007.11.013_bib43","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/hep.1840170412","article-title":"Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy","volume":"17","author":"Poupon","year":"1993","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib45","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2001.24034","article-title":"Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver","volume":"33","author":"Beuers","year":"2001","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/labinvest.3700371","article-title":"Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver","volume":"86","author":"Dombrowski","year":"2006","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib48","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1053\/jhep.2001.24171","article-title":"Characterization of the mouse bile salt export pump overexpressed in the baculovirus system","volume":"33","author":"Noe","year":"2001","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib49","doi-asserted-by":"crossref","first-page":"G923","DOI":"10.1152\/ajpgi.00490.2005","article-title":"Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha\/beta in the adaptive response to bile acids","volume":"290","author":"Zollner","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.510250104","article-title":"Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis","volume":"25","author":"Medina","year":"1997","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0016-5085(99)70564-0","article-title":"Assessment of biliary bicarbonate secretion in humans by positron emission tomography","volume":"117","author":"Prieto","year":"1999","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hep.510250303","article-title":"Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis","volume":"25","author":"Jacquemin","year":"1997","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib53","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/gast.2001.23984","article-title":"The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood","volume":"120","author":"Jacquemin","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib54","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1055\/s-2001-19033","article-title":"Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases","volume":"21","author":"Jacquemin","year":"2001","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0016-5085(03)00898-9","article-title":"ABCB4 gene mutation-associated cholelithiasis in adults","volume":"125","author":"Rosmorduc","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.11.013_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-2-29","article-title":"Low phospholipid associated cholelithiasis: association with mutation in the MDR3\/ABCB4 gene","volume":"2","author":"Rosmorduc","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib57","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jhep.2004.08.023","article-title":"Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation","volume":"41","author":"Geuken","year":"2004","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2007.11.013_bib58","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1572-0241.1998.00470.x","article-title":"Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis","volume":"93","author":"Lindor","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib59","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hep.20370","article-title":"Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis","volume":"40","author":"Rost","year":"2004","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2007.11.013_bib60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1590-8658(02)80112-8","article-title":"Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis","volume":"34","author":"Roda","year":"2002","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib61","first-page":"283","article-title":"Biliary secretion of bile acids and lipids in primary sclerosing cholangitis: influence of cholestasis and effect of ursodeoxycholic acid treatment","volume":"23","author":"Stiehl","year":"1995","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib62","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0168-8278(02)00209-X","article-title":"Death receptor-mediated apoptosis and the liver","volume":"37","author":"Yoon","year":"2002","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2007.11.013_bib63","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1172\/JCI1325","article-title":"A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation","volume":"101","author":"Rodrigues","year":"1998","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03401914","article-title":"Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production","volume":"4","author":"Rodrigues","year":"1998","journal-title":"Mol Med"},{"key":"10.1016\/j.cld.2007.11.013_bib65","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0168-8278(06)80299-0","article-title":"Glycochenodeoxycholic acid at moderate levels induces apoptosis independent of FAS\/CD95 and caspase 8 in human liver cell lines","volume":"44","author":"Rust","year":"2006","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2362.2000.00615.x","article-title":"Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes","volume":"30","author":"Benz","year":"2000","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib67","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.toxlet.2006.06.006","article-title":"Involvement of endoplasmic reticulum in glycochenodeoxycholic acid-induced apoptosis in rat hepatocytes","volume":"166","author":"Tsuchiya","year":"2006","journal-title":"Toxicol Lett"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib68","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/jhep.2002.35441","article-title":"Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation","volume":"36","author":"Xie","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib69","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib70","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2007.11.013_bib71","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib72","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2005-916323","article-title":"The natural history of PBC: has it changed?","volume":"25","author":"Lee","year":"2005","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib73","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-2002-34506","article-title":"Immunopathogenesis of primary biliary cirrhosis","volume":"22","author":"Nishio","year":"2002","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib74","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.mcg.0000225653.07932.8f","article-title":"Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy","volume":"41","author":"Lazaridis","year":"2007","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib75","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1572-0241.2000.01857.x","article-title":"Impact of fatigue on the quality of life of patients with primary biliary cirrhosis","volume":"95","author":"Huet","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib76","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jhep.2005.09.004","article-title":"The pruritus of cholestasis","volume":"43","author":"Bergasa","year":"2005","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib77","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(89)91698-3","article-title":"Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial","volume":"97","author":"Leuschner","year":"1989","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib78","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib79","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib80","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib82","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","author":"Poupon","year":"2003","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib83","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib84","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"9204","key":"10.1016\/j.cld.2007.11.013_bib85","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)72401-6","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"355","author":"Lindor","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib86","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib87","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib88","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2007.11.013_bib89","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic acid\u2013treated patients with primary biliary cirrhosis: results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib90","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/00365529709000190","article-title":"Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis: a Swedish multicentre, double-blind, randomized controlled study","volume":"32","author":"Eriksson","year":"1997","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib91","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1572-0241.2004.04047.x","article-title":"Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis","volume":"99","author":"Combes","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"9184","key":"10.1016\/j.cld.2007.11.013_bib92","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002234.pub2","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gluud","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.cld.2007.11.013_bib94","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib95","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0168-8278(92)90065-W","article-title":"A controlled trial of prednisolone treatment in primary biliary cirrhosis: three-year results","volume":"15","author":"Mitchison","year":"1992","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib96","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8278(96)80327-8","article-title":"Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis","volume":"25","author":"Leuschner","year":"1996","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib97","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib98","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib99","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib100","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib101","first-page":"168","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Talwalkar","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib102","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000048854","article-title":"Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"64","author":"Holtmeier","year":"2001","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib103","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib104","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1572-0241.2002.05703.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system","volume":"97","author":"Talwalkar","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouilleres","year":"2006","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib106","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes","volume":"102","author":"Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib107","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/CRIAI:28:2:105","article-title":"Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis","volume":"28","author":"Schramm","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib108","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-2005-916326","article-title":"Future treatment options in PBC","volume":"25","author":"Vierling","year":"2005","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib109","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.21741","article-title":"Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid","volume":"46","author":"Stojakovic","year":"2007","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.cld.2007.11.013_bib110","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJM199504063321406","article-title":"Primary sclerosing cholangitis","volume":"332","author":"Lee","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib111","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3109\/00365528709011139","article-title":"Primary sclerosing cholangitis: a long-term follow-up study","volume":"22","author":"Aadland","year":"1987","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib112","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2006-933559","article-title":"Etiopathogenesis of primary sclerosing cholangitis","volume":"26","author":"O'Mahony","year":"2006","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib113","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-2006-933560","article-title":"Primary sclerosing cholangitis: epidemiology, natural history, and prognosis","volume":"26","author":"Levy","year":"2006","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib114","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.21337","article-title":"Primary sclerosing cholangitis: summary of a workshop","volume":"44","author":"Larusso","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-2006-933562","article-title":"Primary sclerosing cholangitis and cholangiocarcinoma","volume":"26","author":"Lazaridis","year":"2006","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib116","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2006-933561","article-title":"Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer","volume":"26","author":"Broome","year":"2006","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib117","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-2006-933563","article-title":"The medical management of primary sclerosing cholangitis","volume":"26","author":"Cullen","year":"2006","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib118","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib119","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0168-8278(05)80467-2","article-title":"Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis: a 3-year pilot study with a placebo-controlled study period","volume":"20","author":"Stiehl","year":"1994","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib120","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/hep.1840140516","article-title":"Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study","volume":"14","author":"O'Brien","year":"1991","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2007.11.013_bib121","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group","volume":"336","author":"Lindor","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003626","article-title":"Bile acids for primary sclerosing cholangitis","author":"Chen","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2007.11.013_bib123","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(03)00006-0","article-title":"Current management of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"38","author":"Levy","year":"2003","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib124","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","article-title":"A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis","volume":"121","author":"Mitchell","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib125","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","article-title":"High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis","volume":"96","author":"Harnois","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib126","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2007.11.013_bib127","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0168-8278(06)80635-5","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"44","author":"Cullen","year":"2006","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0168-8278(01)00251-3","article-title":"Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment","volume":"36","author":"Stiehl","year":"2002","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib129","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.gtc.2006.07.003","article-title":"Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease","volume":"35","author":"Chan","year":"2006","journal-title":"Gastroenterol Clin North Am"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","article-title":"Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"124","author":"Pardi","year":"2003","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2007.11.013_bib131","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2036.2005.02650.x","article-title":"The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis","volume":"22","author":"Wolf","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib132","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","article-title":"Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"134","author":"Tung","year":"2001","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.cld.2007.11.013_bib133","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/jlts.2003.50169","article-title":"Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list","volume":"9","author":"Brandsaeter","year":"2003","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib134","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1572-0241.2002.05585.x","article-title":"Management of primary sclerosing cholangitis","volume":"97","author":"Lee","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib135","first-page":"57","article-title":"The combination of prednisone and colchicine in patients with primary sclerosing cholangitis","volume":"86","author":"Lindor","year":"1991","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2007.11.013_bib136","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1111\/j.1572-0241.2000.02323.x","article-title":"Oral budesonide in the treatment of primary sclerosing cholangitis","volume":"95","author":"Angulo","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2007.11.013_bib137","doi-asserted-by":"crossref","first-page":"943","DOI":"10.7326\/0003-4819-131-12-199912210-00006","article-title":"Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis: a case series","volume":"131","author":"Schramm","year":"1999","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.cld.2007.11.013_bib138","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2036.2004.02214.x","article-title":"A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis","volume":"20","author":"Sterling","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib139","first-page":"511","article-title":"Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study","volume":"91","author":"Lindor","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib140","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial","volume":"40","author":"Farkkila","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib141","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004836-200012000-00005","article-title":"An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis","volume":"31","author":"Duchini","year":"2000","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2007.11.013_bib142","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/j.1572-0241.2000.02324.x","article-title":"A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis","volume":"95","author":"Bharucha","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/B:DDAS.0000011827.87103.2e","article-title":"A pilot study of etanercept in the treatment of primary sclerosing cholangitis","volume":"49","author":"Epstein","year":"2004","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib144","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1013240225965","article-title":"Pirfenidone in the treatment of primary sclerosing cholangitis","volume":"47","author":"Angulo","year":"2002","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib145","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/0016-5085(88)90180-1","article-title":"Prospective trial of penicillamine in primary sclerosing cholangitis","volume":"95","author":"Larusso","year":"1988","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib146","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1172-2-26","article-title":"Intrahepatic cholestasis of pregnancy","volume":"2","author":"Pusl","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib147","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0168-8278(00)80139-7","article-title":"Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management","volume":"33","author":"Lammert","year":"2000","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib148","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/hep.21156","article-title":"Intrahepatic cholestasis of pregnancy: a heterogeneous group of pregnancy-related disorders?","volume":"43","author":"Beuers","year":"2006","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2007.11.013_bib149","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1471-0528.1988.tb06791.x","article-title":"Fetal outcome in obstetric cholestasis","volume":"95","author":"Fisk","year":"1988","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib150","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0002-9378(94)70304-3","article-title":"Intrahepatic cholestasis of pregnancy: a retrospective case-control study of perinatal outcome","volume":"170","author":"Rioseco","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"6014","key":"10.1016\/j.cld.2007.11.013_bib151","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/bmj.1.6014.870","article-title":"Fetal complications of obstetric cholestasis","volume":"1","author":"Reid","year":"1976","journal-title":"Br Med J"},{"issue":"4 Pt 1","key":"10.1016\/j.cld.2007.11.013_bib152","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0002-9378(96)80031-7","article-title":"Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management","volume":"175","author":"Alsulyman","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib153","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/hep.20336","article-title":"Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates","volume":"40","author":"Glantz","year":"2004","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib154","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1053\/j.gastro.2005.06.019","article-title":"Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy","volume":"129","author":"Kondrackiene","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib155","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.20952","article-title":"Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid","volume":"42","author":"Glantz","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib156","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1515\/JPM.2006.077","article-title":"Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy","volume":"34","author":"Binder","year":"2006","journal-title":"J Perinat Med"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib157","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1478-3231.2004.0996.x","article-title":"Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a 12-year experience","volume":"25","author":"Zapata","year":"2005","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib158","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/hep.510230627","article-title":"Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis","volume":"23","author":"Colombo","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib159","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hep.510270126","article-title":"A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease","volume":"27","author":"Lindblad","year":"1998","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00365529709007686","article-title":"Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease: results of a randomized study with 1-year follow-up","volume":"32","author":"van de Meeberg","year":"1997","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib161","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib162","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.mpg.0000178086.44155.73","article-title":"Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid","volume":"41","author":"Smith","year":"2005","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cld.2007.11.013_bib163","first-page":"541","article-title":"Use of colesevelam hydrochloride (Welchol) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease","volume":"34","author":"Berg","year":"2001","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib164","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind, crossover, randomized trial","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib165","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF01300759","article-title":"Treatment of pruritus of primary biliary cirrhosis with rifampin","volume":"36","author":"Podesta","year":"1991","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib166","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long-term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib167","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0016-5085(92)90102-5","article-title":"A controlled trial of naloxone infusions for the pruritus of chronic cholestasis","volume":"102","author":"Bergasa","year":"1992","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib168","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis: a crossover, double blind, placebo-controlled study","volume":"37","author":"Terg","year":"2002","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib169","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.510270307","article-title":"Open-label trial of oral nalmefene therapy for the pruritus of cholestasis","volume":"27","author":"Bergasa","year":"1998","journal-title":"Hepatology"},{"issue":"8855","key":"10.1016\/j.cld.2007.11.013_bib170","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/0140-6736(93)91178-O","article-title":"Improvement of cholestatic pruritus by ondansetron","volume":"341","author":"Schworer","year":"1993","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.cld.2007.11.013_bib171","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199405263302117","article-title":"Ondansetron for pruritus due to cholestasis","volume":"330","author":"Raderer","year":"1994","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cld.2007.11.013_bib172","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00042737-199810000-00010","article-title":"Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial","volume":"10","author":"Muller","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2007.11.013_bib173","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1111\/j.1572-0241.2003.08662.x","article-title":"Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis","volume":"98","author":"Browning","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib174","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib175","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1053\/gast.2002.32993","article-title":"The true impact of fatigue in primary biliary cirrhosis: a population study","volume":"122","author":"Goldblatt","year":"2002","journal-title":"Gastroenterology"},{"issue":"894","key":"10.1016\/j.cld.2007.11.013_bib176","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/pmj.76.894.199","article-title":"Primary biliary cirrhosis: new perspectives in diagnosis and treatment","volume":"76","author":"Prince","year":"2000","journal-title":"Postgrad Med J"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib177","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2036.2003.01398.x","article-title":"Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial","volume":"17","author":"Prince","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS19990372","article-title":"Fatigue in chronic disease","volume":"99","author":"Swain","year":"2000","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib179","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/hep.20698","article-title":"A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue","volume":"41","author":"Theal","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.11.013_bib180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-230X-4-13","article-title":"Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial","volume":"4","author":"ter Borg","year":"2004","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2007.11.013_bib181","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s10620-006-9397-5","article-title":"Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial","volume":"51","author":"Talwalkar","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib182","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.21230","article-title":"Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence","volume":"44","author":"Newton","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib183","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","article-title":"An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis","volume":"25","author":"Jones","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib184","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1590-8658(03)00078-1","article-title":"Osteoporosis: still a typical complication of primary biliary cirrhosis?","volume":"35","author":"Solerio","year":"2003","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib185","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2006.09.012","article-title":"Fracture risk in people with primary biliary cirrhosis: a population-based cohort study","volume":"131","author":"Solaymani-Dodaran","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2007.11.013_bib186","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/gut.50.suppl_1.i1","article-title":"Guidelines on the management of osteoporosis associated with chronic liver disease","volume":"50","author":"Collier","year":"2002","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib187","first-page":"389","article-title":"Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?","volume":"21","author":"Lindor","year":"1995","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2007.11.013_bib188","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/gut.49.2.282","article-title":"Osteoporosis in primary biliary cirrhosis revisited","volume":"49","author":"Newton","year":"2001","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2007.11.013_bib189","first-page":"47","article-title":"Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment","volume":"89","author":"Crippin","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0270-9139(94)90098-1","article-title":"Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis","volume":"20","author":"Camisasca","year":"1994","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib191","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1478-3231.1999.tb00034.x","article-title":"Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis","volume":"19","author":"Olsson","year":"1999","journal-title":"Liver"},{"issue":"5","key":"10.1016\/j.cld.2007.11.013_bib192","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2036.2004.01890.x","article-title":"Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial","volume":"19","author":"Pereira","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2007.11.013_bib193","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.cld.2007.11.013_bib194","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib195","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00001703-200312000-00001","article-title":"Hormone replacement therapy update: who should we be prescribing this to now?","volume":"15","author":"Kocjan","year":"2003","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib196","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0168-8278(00)80118-X","article-title":"Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial","volume":"33","author":"Lindor","year":"2000","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2007.11.013_bib197","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2007.11.013_bib198","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Guanabens","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2007.11.013_bib199","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.dld.2007.02.005","article-title":"A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis","volume":"39","author":"Floreani","year":"2007","journal-title":"Dig Liver Dis"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107001213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107001213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T06:22:30Z","timestamp":1630650150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326107001213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":199,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S1089326107001213"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2007.11.013","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}